Posted by SLS on August 11, 2015, at 14:00:12
In reply to Vortioxetine in depression: No hint of added benef, posted by PeterMartin on August 11, 2015, at 11:51:42
> Vortioxetine (trade name: Brintellix) has been approved since December 2013 for the treatment of depression in adults, but did not become actually available before May 2015. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier because it contained no data evaluable for the assessment.
>
> More:
>
> http://medicalxpress.com/news/2015-08-vortioxetine-depression-hint-added-benefit.htmlI have not seen the statistics on the efficacy of vortioxetine. Even if there is no "added benefit" in terms of pecentage of responders, that in no way portrays its true worth as a treatment. For instance, if fluoxetine (Prozac) and vortioxetine both produce a rate of response of 50%, it is conceivable that between the two drugs, 100% of people will benefit from drug treatment. For every new drug that comes to market, a certain percentage of previously treatment-resistant people will go on to respond to it. Some people are responders to reboxetine. It is their miracle drug, despite its reputation for being an inferior drug.
Being treatment-resistant, I welcome the appearance of new drugs, even if they are theoretically "me too" drugs. Obviously, our theories regarding mental illness are inadequate, so I think it is foolish to think that any two drugs can be identical in physiological or clinical effects. The ability to predict the worth of drugs based solely upon pharmacology has been elusive.
How are things going with you?
- ScottSome see things as they are and ask why.
I dream of things that never were and ask why not.- George Bernard Shaw
poster:SLS
thread:1081276
URL: http://www.dr-bob.org/babble/20150806/msgs/1081277.html